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Abstract
Background: Our previous work has provided strong evidence that the transcription factor SOX9 is completely needed for
chondrogenic differentiation and cartilage formation acting as a ‘‘master switch’’ in this differentiation. Heterozygous
mutations in SOX9 cause campomelic dysplasia, a severe skeletal dysmorphology syndrome in humans characterized by a
generalized hypoplasia of endochondral bones. To obtain insights into the logic used by SOX9 to control a network of
target genes in chondrocytes, we performed a ChIP-on-chip experiment using SOX9 antibodies.
Methodology/Principal Findings: The ChIP DNA was hybridized to a microarray, which covered 80 genes, many of which
are involved in chondrocyte differentiation. Hybridization peaks were detected in a series of cartilage extracellular matrix
(ECM) genes including Col2a1, Col11a2, Aggrecan and Cdrap as well as in genes for specific transcription factors and
signaling molecules. Our results also showed SOX9 interaction sites in genes that code for proteins that enhance the
transcriptional activity of SOX9. Interestingly, a strong SOX9 signal was also observed in genes such as Col1a1 and Osx,
whose expression is strongly down regulated in chondrocytes but is high in osteoblasts. In the Col2a1 gene, in addition to
an interaction site on a previously identified enhancer in intron 1, another strong interaction site was seen in intron 6. This
site is free of nucleosomes specifically in chondrocytes suggesting an important role of this site on Col2a1 transcription
regulation by SOX9.
Conclusions/Significance: Our results provide a broad understanding of the strategies used by a ‘‘master’’ transcription
factor of differentiation in control of the genetic program of chondrocytes.
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Introduction
The transcription factor SOX9 plays a critical role in cell fate
decisions of a discrete number of cell types [1–4]. Heterozygous
mutations in Sox9 cause Campomelic Dysplasia (CD), a general-
ized disease of cartilage characterized by hypoplasia of endochon-
dral bones [5,6]. Conditional inactivation of the Sox9 gene at
various times during mouse limb development also demonstrated
that SOX9 is necessary for mesenchymal condensations, for the
commitment to the chondrocyte fate at the time when the
chondrocyte and osteoblast lineages segregate from a common
progenitor, and for the overt differentiation of these cells into
chondrocytes. SOX9 thus acts as a master regulator of
chondrocyte differentiation [7,8]. Chondrogenesis is associated
with activation of a repertoire of cartilage-specific ECM genes. In
several of these genes, chondrocyte-specific enhancers have been
identified. These enhancers contain binding sites for SOX9 and
mutations in these sites strongly decrease or abolish the activity of
these enhancers in transfection experiments and in transgenic mice
[9–12]. SOX9 functions as a transcription factor by recognizing a
specific heptameric DNA sequence (A/T)(A/T)CAA(A/T)G
through its high mobility group (HMG)-box domain. The
characterization of SOX9 dimerization mutants identified in
some CD patients, suggests that SOX9 binds to an inverted repeat
of the heptameric sequence and that this dimeric binding is
necessary for the SOX9-dependent expression of chondrocyte-
related genes [13]. Chondrogenesis is also controlled by a complex
interplay of signaling molecules among which some target either
the expression or the activity of SOX9. Whereas IL-1 and TNF a
inhibit its expression [14], FGF signaling increases its expression
and its activity [15]; Wnt/b-catenin also inhibits its activity and
expression [16], whereas PTHrP increases its activity [17]. In
order to determine whether genes involved in cartilage function
and regulation are direct targets of SOX9 in the genome of
chondrocytes, and to examine patterns of SOX9 interactions with
the chromatin of these genes in these cells, we have used a
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10113chromatin immunoprecipitation (ChIP)-on-chip approach [18].
Our study, which identified many new direct targets of SOX9 as
well as potential binding sites for SOX9 in these genes, provides
new insights in the strategies used by SOX9 in the control of
chondrogenesis. In addition, characterization of a novel SOX9-
dependent activator segment in intron 6 of Col2a1 revealed that
this site appears to be depleted of nucleosomes.
Results
Construction of the array for ChIP-on-chip
As chromatin source for ChIP-on-chip experiments, we used rat
chondrosarcoma cells (RCS cells), because these cells display many
chondrogenic characteristics including secretion of specific carti-
lage ECM proteins and high contents of SOX9, SOX5 and SOX6
[19]. When the expression levels of several mRNAs in RCS cells
were compared to those in Rat-2 fibroblast cells (Figure S1 and
Table S3), the transcription factors, SOX9, SOX5 and SOX6
were expressed at higher levels in RCS cells compared to Rat-2
fibroblast cells. The mRNAs for matrix proteins specific for
chondrocytes including Col2a1, Col11a1, Matrilin-1, Aggrecan,
Syndecan-3, Cdrap, Fibromodulin and Prelp were also highly expressed
in RCS cells. On the other hand, the Col1a1 gene was expressed at
high level in Rat-2 cells but was not expressed in RCS cells. These
results in addition to the previously reported data [19] indicate
that RCS cells maintain a chondrocyte specific phenotype.
Table 1 lists the 80 genes that were placed on the high density
custom oligonucleotide array. Each gene was covered from 15 kb
59of exon 1 to 10 kb 39of the last exon with overlapping 50 mers,
the overlap consisting of 22 bases with the preceding oligonucle-
otide. Oligonucleotides for both sense and antisense strands of
each gene were printed on the array. The sheared, cross-linked
chromatin fragments of rat chondrosarcoma (RCS) cells [19] were
immunoprecipitated with either SOX9 antibodies or with non-
specific IgGs. The DNAs of both anti-SOX9 and non-specific IgG
precipitated chromatin fragments were PCR amplified, labeled
and then hybridized to identical oligonucleotide arrays. In
selecting the genes to be placed on the array, our major rationale
was to examine genes that had been shown to be expressed in
cartilage. This list of genes shown in Table 1 is divided into three
groups. One corresponds to genes for extracellular matrix (ECM)
components. We also placed several genes for small leucine-rich
proteins on the array, since mutations in some of these genes lead
to osteoarthritis [20]. This first group further includes genes for
AdamTS 5 [21], MMP9 and 13 [22], and also Cathepsin B [23], all of
which are involved in ECM turnover. Other genes of group 1 also
include the chains of type I collagen, which are not expressed in
chondrocytes but are prominent in both SOX9-expressing
mesenchymal precursors and in osteoblasts [24]. The second
group was composed of genes for transcription factors including
genes that have a major role in chondrocyte differentiation, such
as Sox9, Sox5 and Sox6, and in cartilage development such as Prx
[25], PGC-1a [26], TCF4 [27], Lef1 [28], b-catenin [29], Stat1 [30]
and TIP60 [31]. This group also included genes with a role in the
osteoblasts differentiation, namely Runx2 [32] and Osterix (Osx)
[33]. This group further included genes for transcription factors
expressed in an altogether different lineage such as MyoD [34] and
Myogenin [35], which are not expressed in chondrocytes. The third
group consisted of genes for signaling molecules involved in limb
development or in various steps of chondrogenesis. These included
genes for Integrins a11 [36], BMP2 and 4 [37], the BMP antagonists
Noggin [37] and Chordin [38], TGFb3 [39], different Wnts [29],
Patched [40], Ihh [41], Shh [42], Smoothened [43], VEGF [44], Ctgf
[45], Egf and Egfr [46], Igf1 and Igf2r [47], PTHrP [48], Grb10 [49],
TNF a [50], IL1a [51], PKC and p38 [52], Fgfr3 [53], PKA [54],
Ncam [55], a-Catenin [56], and CD44 [57].
Criteria for positive SOX9 interaction sites
Because the sheared chromatin fragments had a size between 1
and 1.5 kb, the peaks of hybridization were relatively broad. To be
Table 1. List of genes placed on the array.
Gens for Extracellular Matrix Proteins Genes for Transcription Factors Genes for Signaling Molecules
Col2a1 Matrilin 1 Sox9 BMP2 CTGF
Col9a2 Matrilin 3 Sox5 BMP4 TGF-b1
Col11a1 Matrilin 4 Sox6 Noggin TGF-b3
Col11a2 Cdrap TCF4 Chordin Grb10
Col3a1 Cthrc1 Lef1 Wnt3a Integrin-a11
Col1a1 Adam-TS5 Stat1 Wnt5a NCAM
Col1a2 MMP9 Tip60 Wnt7a ERK1
Aggrecan MMP13 PGC-1a Wnt9 ERK2
Syndecan-3 Cathepsin B b-catenin Shh p38
Fibronectin Chondroadherin Runx2 Patched PKA
Linkprotein Lubricin Osx Smoothened PKCa
Asporin Prelp Myogenin PTHrP Arhj
Biglycan Osteoadherin MyoD FGFR3 CD44
Decorin Epiphycan EGF Asb4
Fibromodulin Osteoglycin EGFR a-catenin
Lumican Opticin IGF1 TNF-a
IGF2r IL-1a
VEGF
doi:10.1371/journal.pone.0010113.t001
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heights at identical locations on both the forward and reverse
DNA strand lanes. A so called smoothened lane was generated by
subtracting the corresponding non-specific IgG hybridization
signals from each SOX9 signal followed by averaging the two
subtracted signals. Overall, except for a few genes discussed below,
peaks, which on the ‘‘smoothened’’ lane had a cut off above the
base 2 logarithm of 1.5 were further examined.
Location of SOX9 interaction peaks
Figure 1 illustrates examples of actual hybridization results for
two genes in which SOX9 interaction sites were identified. Two
clear peaks were identified in Col2a1. The center of the peak
located in intron 1 corresponds to a previously identified
chondrocyte-specific enhancer in this gene [9]. The other peak
is located in intron 6 and the characterization of this SOX9
interaction site will be presented in a subsequent section, that is
SOX9 binds to intron 6 of Col2a1. Two SOX9 interaction sites
were also identified in the Col11a2 gene. The centers of these
hybridization peaks, one located in the promoter and the other in
intron 1, correspond to previously characterized chondrocyte-
specific enhancers [10]. Identification of clear ChIP hybridization
peaks centered at previously characterized chondrocyte-specific
enhancers suggested that the hybridization peaks in other genes on
the array might also correspond to bona fide specific SOX9
interaction sites. A total of 55 peaks with a cut off .log2 1.5 were
identified in 30 genes. These genes and the locations of these peaks
within these genes are listed in Table 2. A majority of the peaks
were located either in promoters or in 59 introns, rarely in regions
39 to the gene. Most genes for cartilage-specific ECM components,
contain at least two SOX9 interaction peaks. These include, in
addition to Col2a1 and Col11a2 [10], Col9a2 [58], Syndecan-3 [59],
Aggrecan [12], Epiphycan [60], Chondroadherin [61] and Biglycan [62].
A few genes, which have smoothened peaks below but close to the
log2 1.5 cut off, are, however, also likely to be direct targets of
SOX9 and are likely to be part of the genetic program of
chondrocytes controlled by SOX9. These genes are listed in a
separate section of Table 2. Interestingly the Col1a1 gene, which is
not expressed in chondrocytes but is prominently expressed in
mesenchymal precursors and in osteoblasts contains two SOX9
interaction peaks. Similarly the genes for Osx and Runx2,
transcription factors required for osteoblast differentiation, contain
distinct SOX9 interaction sites. One possible hypothesis is that at
these sites in chondrocytes SOX9 might be part of repressor
complexes. Table 3 lists the genes in which no SOX9 interaction
sites were identified. This list includes the MyoD and Myogenin
genes, which are master transcription factors for myoblast
differentiation and are not expressed in chondrocytes. Other
genes in this group include MMP13, those for several small
leucine-rich proteoglycans, also the Wnt 3a, 5a, 7a, 9, Ihh and Shh
genes. One surprise is that no clear SOX9-interaction site was
found in the Sox6 gene, which together with Sox5, is required for
overt chondrocyte differentiation and requires SOX9 for expres-
sion [8].
SOX9 binding to specific sequences in peaks of
hybridization
We identified potential dimeric SOX9 binding sequences in
peaks and verified SOX9 binding by electrophoretic mobility shift
assay (EMSA) for 11 of these sites (Figure 2). These eleven sites
included the sites that had been already confirmed to be SOX9
binding sites. They included sites in intron 1 of Col2a1, Col11a1,
Col11a2 and Cdrap. The reason we chose these sites is that by
analyzing the sites by EMSA, we could validate that the ChIP-on-
chip peaks revealed true SOX9 binding sites. We chose the other
sites based on potential SOX9 binding sequences within the peaks
of hybridization. The potential SOX9 binding sites in most of
these genes diverged from the consensus binding sites,
WWCAAWG(N)nCWTTGWW (W is A or T, N is non-specific
base and n shows number of N) and SOX9 was indeed bound to
each of these sequences. By comparing the mobility of SOX9-
DNA complexes with that of a binding site in an enhancer in
intron 1 of Col2a1, we concluded that SOX9 was mainly binding
as a dimer to each of the peak sequences. We also asked whether
Figure 1. Identification of SOX9 interaction sites in rat Col2a1 and Col11a2 genes by ChIP-on-chip. ChIP-on chip using SOX9 antibody
showed specific hybridization peaks, which were further modified by background subtraction to form smoothened peaks shown at the bottom of
each panel. Exons are shown as solid bars. In the Col2a1 gene (left panel), we clearly detected two peaks, one in intron 1 and the other in intron 6. In
the Col11a2 gene (right panel), we clearly detected two peaks, one in the promoter region and the other in intron 1. Exons shown in the right side of
exon 1 in Col11a2 were those in the adjacent gene.
doi:10.1371/journal.pone.0010113.g001
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in the 610 bp centered on the hybridization peaks were different
from 610 bp sequences surrounding random potential SOX9
binding sites outside the peaks. The conservation scores were
higher in peaks than in non-peak DNA sequences (Figure S2). The
AT content in the peaks was significantly lower than that in the
non-peak regions indicating that SOX9 preferentially interacts
with its binding sites when it is surrounded by sequences with a
higher GC content (Figure S3).
SOX9 binds to intron 6 of Col2a1
In addition to the hybridization peak centered on a previously
identified chondrocyte-specific enhancer in intron 1 of Col2a1,a
peak was identified in intron 6 (Figure 1, left). To validate this
result we performed real-time quantitative PCR with intron 6
probes centered on the middle of the intron 6 peak using ChIP
DNA generated with SOX9 antibodies. The results showed a
strong signal for this DNA segment that scored higher than the
DNA segment in intron 1, whereas a control segment at the 39 end
of the Col2a1 gene gave no signal (Figure S4). A potential SOX9
dimeric binding site was identified in the PCR amplified segment
and EMSA confirmed that recombinant SOX9 did indeed bind to
this DNA segment as a dimer (see Figure 2). We concluded that in
chondrocytes, SOX9 interacts with a specific site in the chromatin
of intron 6 of the Col2a1.
Intron 6 segment is likely to contribute transcriptional
activity
A multimerized 48 bp segment in intron 1 of Col2a1 was
previously shown to have strong SOX9-dependent enhancer
activity [9]. A similar reporter construct was generated using a 48-
bp sequence in the intron 6 segment that binds SOX9 in EMSA.
However, the multimerized segment of intron 6 did not show
SOX9-dependent enhancer activity (Figure S5 A and B). When
the two multimerized sequences were placed in tandem in the
reporter construct, the intron 6 sequence did not significantly
increase or decrease the SOX9-dependent activity of the intron 1
enhancer in either 293T cells or RCS cells (Figure S5 A and B).
The 39 part of the 48-bp sequence in intron 1 contains a dimeric
inverted repeat SOX9 binding site, whereas the 59 part consists of
a direct repeat of monomeric SOX9 binding sites (Figure 3A).
When the rat intron 6 sequence was aligned with the
corresponding mouse and human sequences, the mouse sequence
in the 39 region of the 48 bp was completely conserved. The
human sequence in this region was not identical to rat or mouse
sequences. However, the human sequence binds SOX9 efficiently
in EMSA (Figure S6). Then, to test whether the inverted repeat
SOX9 binding site in intron 6 could replace the inverted repeat
site in the 39 part of the 48-bp intron 1 sequence, two chimeric 48-
bp sequence segments were generated as illustrated in Figure 3
and multimerized as in the original intron 1 and intron 6 vectors.
Table 3. Genes which do not contain ChIP hybridization peaks.
Extracellular Matrix Proteins Transcription Factors Signaling Molecules
Col1a2 Col3a1 MMP13 Sox6 TCF4 TGFb1 EGF BMP2 IGF1
Cthrc1 Lubricin Matrilin 3 MyoD Myogenin TNFa FGFR3 Integrin a11 Arhj
Osteoadherin Osteoglycin Asporin b-catenin PGC-a Shh Wnt3a Wnt5a Wnt7a
Lumican Opticin Decorin Wnt9 NCAM CD44 Asb4
doi:10.1371/journal.pone.0010113.t003
Figure 2. Validation of SOX9 binding motifs by EMSA. EMSA was performed as described in Materials and Methods using SOX9 binding motifs
found at or near the center of the hybridization peaks in each gene. Suppl. Table S1 lists the sequences of the probes used. The mobility of
32P
labeled probe bound to purified SOX9 was consistent with a complex containing mainly a SOX9 dimer. The amount of SOX9 used in each panel was
0, 20 or 40 ng.
doi:10.1371/journal.pone.0010113.g002
SOX9 Interaction Sites
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replaced with that of intron 6 (Chimera B), the resultant activity
became similar to that of the intron 1 48-bp in RCS cells.
Replacement of the 59 sequence of the intron 1 48-bp segment
with the 59 sequence of the intron 6 48-bp (Chimera A) reduced
the activity of the enhancer almost 20-fold in RCS cells. These
results strongly suggested that the 59 part of the intron 1 sequence
has an important role in the Chimera B activity. In the presence of
this sequence, the inverted repeat SOX9 binding site in the intron
6 segment is likely to contribute transcriptional activity in RCS
cells (Figure 3B). Further when this inverted repeat sequence was
mutated, SOX9 binding was abolished and the mutated Chimera
B did not show any activity (Figure S7).
Increase in intron 1 enhancer activity in the presence of
intron 6
Although a short amplified segment of intron 6 was inactive, this
DNA segment appeared to become active when juxtaposed to the
59 segment of the intron 1 fragment. The construct containing a
3kb Col2a1 promoter, exon 1 with a mutation in the ATG
translation initiation site and 3kb of intron 1 followed by the b-geo
reporter (construct a in Figure 4) has been shown to display strong
chondrocyte-specific b-galactosidase expression in transgenic mice
[63]. We then inserted the entire 1kb intron 6 sequence (construct
b in Figure 4) or an intron 6 from which the SOX9 binding motif
was deleted (construct c in Figure 4) into 39 of the b-geo polyA
signal. In transfection experiments the intron 6-containing
reporter (construct b in Figure 4) was three times more active
than the vector containing no intron 6. When the SOX9 motif was
deleted from intron 6, the activity was decreased by about 40%.
The results of these experiments suggested that the SOX9 binding
motif in intron 6 might act as an enhancer and have a role in
activation of the Col2a1 gene. However, the precise role of this
segment in the regulation of Col2a1 gene in vivo remains to be
clarified.
Histone-poor SOX9 binding segment in intron 6 in
chondrocytes
Judging from the experiments shown in Figure 4, the function of
the SOX9 binding motif in intron 6 could be different from that in
intron 1 in the Col2a1 gene. Since histone modifications control
chromatin’s function in the regulation of gene expression [64], we
compared the status of several histone H3 modifications around
the SOX9 binding sites in intron 6 with those in other introns.
These experiments revealed that the levels of histone H3 in intron
6 were clearly lower than those in intron 1 and much lower than
those in intron 9, a segment with which SOX9 is not interacting
(Figure 5A). The levels of H3K14ac, a marker of active chromatin,
were also much reduced in intron 6 compared to their much
higher levels in introns 1 and 9 (Figure 5B). This finding was in
agreement with the low level of histone H3 in intron 6 (Figure 5A).
As expected the levels of H3K9ac and H3K4me3 were high in
intron 1 but low in introns 6 and 9, because the levels of both
markers are high at the 59 end of active genes, but decrease toward
the 39 segments (Figure 5B). When the occupancies of SOX9 and
histone H3 were compared in the Col2a1 segments immediately
surrounding intron 6, the high occupancy of SOX9, and the very
low occupancy of histone H3 were restricted to intron 6
(Figure 5C). Overall these results strongly suggest that the
chromatin segment surrounding the SOX9 binding site in intron
6 was depleted of nucleosomes. We then asked whether the
absence of histone H3 in intron 6 was also found in the chromatin
of a cell type that does not express Col2a1. Figure 5D shows that
histone H3 occupancy in intron 6 of Col2a1 in Rat-2 fibroblasts, in
which Col2a1 is not expressed, was much higher than in RCS cells.
The occupancy of the active gene marker, H3K9ac was low in the
different segments of Col2a1 in Rat-2 fibroblast, compared to its
higher occupancy in the promoter region of the cyclin B1 gene,
which is active in Rat-2 fibroblast. Further we performed Chip-
qPCR with SOX9 and H3 antibodies using two additional cell
types, one consists of mouse primary rib chondrocytes that express
Figure 3. Functional analysis of SOX9 interaction site in intron 6. A: The 48 bp intron6 (+6676 to +6724) of rat was aligned with the
corresponding sequences of mouse and human Col2a1 gene. The putative SOX9 binding sites were underlined. B: Left; Schematic representation of
chimera constructs. The sequences of a 48 bp segment in intron 1 and intron 6 are shown above each construct in a and b. The bases written by bold
letters indicated the putative SOX9 binding sites. The 59 region in intron 1 contained dimeric direct repeat, and 39 regions of both intron 1 and intron
6 contained inverted repeats. Right; Each chimera construct consisted of five tandem repeats followed by a Col2a1 minimal promoter (89bp) [73] and
the Firefly luciferase gene and transfected in RCS cells. The values of luciferase activity were normalized by adjusting the activity of construct (a) as
1.00.
doi:10.1371/journal.pone.0010113.g003
SOX9 Interaction Sites
PLoS ONE | www.plosone.org 6 April 2010 | Volume 5 | Issue 4 | e10113Col2a1 and Sox9 and the other is a human lymphoblast cell line
(Reh) that expresses neither Col2a1 nor Sox9 (Figure S8). Our
results support the hypothesis that the histone-poor region of
intron 6 is specific for the cells that express Col2a1.
Discussion
Our objective was to identify possible SOX9 chromatin
interaction sites among a number of genes, which are believed
to be involved either in chondrocyte differentiation or in
chondrocyte function. The 80 genes, which were placed on a
high density oligonucleotide array, were subdivided in three
groups, namely genes for extra cellular matrix components, for
transcription factors, and for signaling molecules. As chromatin
source for ChIP-on-chip experiments, we used rat chondrosarco-
ma cells (RCS cells), because these cells display many chondro-
genic characteristics including secretion of specific cartilage ECM
proteins and high contents of SOX9, SOX5 and SOX6 (see
Figure S1) [19]. In arrays containing either sense or anti-sense
oligonucleotides the SOX9 interaction profiles showed very similar
patterns of hybridization providing strong evidence for the high
degree of specificity of these hybridization peaks. Further, the
profile of the negative controls using non-specific IgGs showed
essentially no hybridization peaks. Overall these results showed
that the ChIP-on-chip approach was very efficient in identifying
highly specific SOX9 interaction sites. Among the 80 genes placed
on the array, 30 genes showed one or more clear hybridization
peaks. Most of these genes are active during chondrocyte
differentiation and include extracellular matrix (ECM) protein-
coding genes, genes for transcription factors and for signaling
proteins. Our experiments also indicate that among the ECM gene
several genes for small leucine rich proteoglycans show clear
interaction sites for SOX9. Previous experiments identified
functional SOX9 binding sites that control the activity of
chondrocyte-specific transcriptional enhancers in the Col2a1,
Col11a2 [10], Aggrecan [12] and Cdrap [11] genes. Our finding that
the SOX9 hybridization peaks are centered on these previously
identified SOX9 binding sites strongly supports the hypothesis that
the SOX9 interaction sites have a clear biological role. The results
of our ChIP-on-chip experiments revealed that most cartilage
ECM genes contain at least two SOX9 chromatin interaction sites.
These sites are mainly located in promoter regions and in first
introns, some also in other introns, and fewer in 39 un-transcribed
regions. Since promoter and first intron segments contain major
transcriptional regulatory sequences the presence of SOX9
interaction sites in these DNA segments suggests that in these
genes SOX9 may interact with the general transcriptional
machinery.
Figure 4. Stimulation of enhancer activity of intron 1 by intron 6. A: Schematic representation of constructs used. Construct (a) had a 3 kb
promoter, exon 1, a 3 kb intron 1 of Col2a1followed by b-geo as previously shown [73]. Construct (b) had 1kb corresponding to the entire intron 6
itself (+6489 to +7374) in addition to construct (a) just after the polA. In construct (c) the SOX9 binding sequence (48bp, +6676 to +6724) was deleted
from intron 6. B: Each construct (500 ng) was co-transfected into RCS cells with 10 ng of a TK-Renilla luciferase plasmid that served as an internal
control for transfection efficiency. The bars represent b-galactosidase activity of each construct normalized to the internal control (TK-Renilla luciferase
plasmid).
doi:10.1371/journal.pone.0010113.g004
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there is no expression of Sox5 and Sox6 in chondrocytes [8]. Sox5
contains several SOX9 interaction sites located in the promoter,
introns 1 and 2. In contrast, we did not detect SOX9 interaction
sites in the Sox6 gene. This suggests either that the Sox6 gene is not
a direct target of SOX9 or that the SOX9 interaction sites are
located outside the Sox6 DNA segments that were printed on the
array. Our experiments detected interaction sites for SOX9 in the
Sox9 gene located in introns 1 and 2. Although our previous results
have indicated that chondrocyte-specific regulatory segments of
Sox9 were still active even when the Sox9 gene was partially
deleted, it is nevertheless possible that the SOX9 binding sites in
introns 1 and 2 have an autoregulatory role in the transcriptional
control of SOX9 in combination with other transcription factors.
In Sertoli cells SOX9 binds to the promoter region of Sox9 but our
results did not detect a SOX9 interaction sites in the chromatin of
this segment in chondrocytes [65]. The PTHrP receptor is highly
expressed in prehypertrophic chondrocytes where Sox9 is equally
highly expressed. Through this receptor and via PKA, PTHrP
stimulates the phosphorylation of SOX9 [17,54]. This phosphor-
ylation of SOX9 increases its activity [17]. The finding of a SOX9
interaction site in the gene for the PTHrP receptor indicates that
SOX9 interacts with the gene for a component of a signaling
pathway that increases the activity of SOX9. BMP signaling also
plays a major role in chondrocyte differentiation. Finding SOX9
interaction sites in genes of the BMP signaling strongly suggested
that SOX9 is directly implicated in the control of these genes.
Interestingly, the Bmp4 gene itself showed also a SOX9 interaction
site. In addition to the genes specifically expressed in chondrocytes
such as cartilage ECM genes, SOX9 interaction sites were also
detected in ubiquitously expressed genes such as those for the
transcription factors Tip60, Stat1 and Lef1, and for the ERK1,
ERK2 and PKA signaling molecules. Thus in chondrocytes SOX9
also appeared to interact with a number of genes that are more
broadly expressed. For example, we showed recently that Tip60
up-regulated expression of Col2a1, a direct target of SOX9 [31].
Our present data indicated that SOX9 interacted with the Tip60
promoter and up-regulated this promoter (H.Yasuda et al.,
unpublished results). Thus SOX9 interacts with the gene for a
coactivator, which cooperates with SOX9 in activating a
downstream target of SOX9. Previous experiments have shown
that both ERK1 and ERK2 signaling in response to FGF increases
Figure 5. Depletion of histone H3 in intron 6 in RCS cells but not in Rat-2 fibroblast. Histone modification status in the chromatin at
several introns of Col2a1 in RCS cells (A–C) and at the promoter of Col2a1 and Cyclin B1 (CNB1) and introns 1 and 6 of Col2a1 in Rat-2 fibroblasts (D)
was examined by real time quantitative PCR. The ChIP DNA fragments were prepared as described in Materials and Methods using SOX9, H3 (A and
C), H3K9ac, H3K14ac, H3K4me3 (B) and H3, H3K9ac (D) antibodies. The SOX9 hybridization peak in introns together with the partial map of the Col2a1
gene is shown in E.
doi:10.1371/journal.pone.0010113.g005
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to FGF increases SOX9 activity [66]. Interestingly, the well known
Col1a1 gene, which is not expressed in chondrocytes and in RCS
cells, showed two clear interaction sites one in intron1, the other
immediately 39 to the gene. One possible hypothesis is that SOX9,
which is known to be a transcriptional activator, might also be able
to become part of a negative transcriptional complex and that in
chondrocytes SOX9 may have a role in silencing genes that are
active in Sox9-expressing osteochondroprogenitor cells as well as in
osteoblasts. The SOX9 interaction sites in the genes for RUNX2
[32] and OSX [33], two transcription factors that are required for
osteoblast differentiation, may have a similar function. The genes
for two other ‘‘master’’ transcription factors, MyoD [34] and
Myogenin [35] which are not expressed in chondrocytes but are
needed for myoblast differentiation, did not have SOX9
interaction sites consistent with the high degree of specificity of
the role of SOX9 in the chromatin of chondrocytes.
EMSA of a sample of SOX9 interaction sites confirmed that
SOX9 was able to bind to specific sites found in the hybridization
peaks of our ChIP-on-chip experiment. These sequences often
diverged from the consensus dimeric binding sites
WWCAAWGX(N)CWTTGWW (W=A or T) by several mis-
matches. Among the many genes having SOX9 binding sites, the
Col2a1 gene is one that has been most intensively characterized so
far in terms of response to SOX9. In this gene, SOX9 has been
shown to bind to a sequence in a chondrocyte-specific enhancer in
intron 1 and consequently to induce the activity of this enhancer.
As shown here a ChIP-on-chip peak was clearly centered on this
binding site in intron 1. In addition to this peak, another peak was
detected in intron 6 of Col2a1. The binding of SOX9 at this site
was validated by EMSA and ChIP-qPCR. Intron 6 increases the
activity of a reporter containing the Col2a1 promoter and the
enhancer of intron1, and the deletion of a short segment
containing the SOX9 binding site in intron 6 from this reporter
decreased its activity suggesting that this SOX9 binding site
functions as a positive regulatory site in Col2a1. The 39 sequence of
a 48bp of intron 6 contained an inverted repeat sequence similar
to the inverted repeat sequence in the 39segment of the 48bp in
intron 1 (Figure 3). The 39 segment of intron 6 was able to
functionally substitute for the inverted repeat sequence in intron 1
when tested as a chimeric construct containing the 59 part of the
48 bp of intron1. We previously showed that a highly multi-
merized repeat of an 18 bp sequence containing the inverted
repeat in intron 1 was sufficient for enhancer activity in
chondrocytes [67]. A similar construction containing the inverted
repeat of intron 6 was not tested in this study. However, the
function of this region in the regulation of the Col2a1 gene in vivo
still remains to be clarified.
Very interestingly the intron 6 enhancer segment is either very
poor in nucleosomes or free of nucleosomes in chondrocytic cells
(RCS cells and mouse primary rib chondrocyte cells [68]) (Figure 5
and S8). Nucleosome deficient regions in the genome have been
detected in promoter regions of actively transcribed genes, in 39
non-translated segments and in interval sequences between genes
[69–71]. Recently nucleosome-deficient structures were also
shown at several transcription factor binding sites in Saccharomyces
cerevisiae [72,73]. Although the DNA sequence itself plays an
important role in nucleosome occupancy, it is also likely that
competition between the binding of transcription factors to their
recognition sites and of nucleosomes determines their relative
occupancy at specific sites in the genome. Since intron 6 in the
Rat-2 fibroblasts and human lymphoblast, Reh cells, in which
both Col2a1 and Sox9 genes were not actively transcribed, did form
nucleosome structures (Figure 5 and S8), we propose that SOX9 is
part of a large multiprotein complex that occupies the chromatin
in intron 6 in chondrocytes and prevents nucleosome structures to
form. Based on our transfection experiments it is likely that this
complex, together with a SOX9-containing complex that occupies
the enhancer segment in intron 1, interacts with the pre-initiation
complex at the promoter to activate the Col2a1 gene in
chondrocytes. One possible explanation for this nucleosome free
structure is that several transcription factors are recruited, disrupt
the nucleosome structure and bind to this region through the
binding to SOX9. In summary, the ChIP-on-chip experiment
using chondrocyte chromatin has identified SOX9 interaction sites
in a number of genes for components of cartilage as well as for
transcription factors and signaling molecules that participate in the
regulation of the chondrocyte program. Our experiments also
indicate that SOX9 co-opts other genes that are largely ubiquitous
to become part of the SOX9 program in chondrocytes. Because
SOX9 interacts also with genes that are not expressed in
chondrocytes but are expressed in a cell type that is derived from
a common progenitor, SOX9 could have a negative role in these
genes. Other experiments led to the identification of a nucleo-
some-free novel SOX9-dependent segment in the Col2a1 gene.
Overall our experiments are providing new insights in the essential
role of SOX9 in the complexity of the chondrocyte genetic
program.
Materials and Methods
Cell culture
Human HEK293T, Reh cells and Rat fibroblast (Rat-2) were
obtained from American Type Culture Collection (ATCC). Rat
chondrosarcoma (RCS) cells were gifted from Dr. James H.
Kimura, Henry Ford Hospital, Detroit, Michigan [19].
HEK293T, Rat-2, and RCS cells were cultured in DMEM and
Reh cells were in RPMI1640 supplemented with 10% fetal bovine
serum.
ChIP-on-chip and ChIP-qPCR analysis
ChIP was performed according to the previously described
method [74] using the ChIP assay kit (Millipore Co., Ltd). Briefly,
the RCS cells were fixed with formaldehyde and then the
chromatin prepared by sonication was treated with rabbit anti-
SOX9 antibodies (Millipore, AB5809) or non-specific rabbit IgGs.
The resultant DNA fragments were ligated with random
oligonucleotides after the DNA was modified with terminal
deoxyribonucleotide transferase (TdT). The modified anti-SOX9
precipitated and IgG precipitated DNA fragments were amplified
by PCR and further labeled with Cy3 and Cy5, respectively. The
chip array was done by use of NimbleGen platform (NimbleGen).
The ChIP-qPCR experiments were carried out by SYBR Green
PCR Master Mix and ABI7900HT (Applied Biosystems) using
ChIP DNA as a template. ChIP DNA-to-input DNA ratios were
calculated after immunoprecipitation with each antibody. The
data were normalized with IgG control antibody, The primers
used for the qPCR are shown in Suppl. Table S2.
Electrophoretic mobility shift assay
The probes used in EMSA shown in Suppl. Table S1 were
labeled by a
32P-dCTP using Klenow fragment, and then EMSA
was performed using recombinant human SOX9 proteins
expressed in E.coli as described previously [67].
Plasmid construction and reporter assay
Oligonucleotides of 48 base pair fragments of both Col2a1
intron 1 and intron 6 were cloned into pBluescript vector and then
SOX9 Interaction Sites
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reporter assay we used a luc4 reporter plasmid. The intron 6 DNA
was obtained by PCR using Bac CH230-103H12 provided from
BACPAC Resource Center (Oakland, USA) as a template. In the
reporter assay, the cells were co-transfected with an adequate
reporter plasmid, a SOX9 expressing plasmid and a control
plasmid (TK-Renilla luciferase plasmid) using Fugene 6, The
luciferase and b-galactosidase activities were obtained by use of a
dual luciferase assay system (Promega Co. Ltd) and a Tropix
Galacto Reaction kit (Applied Biosystems), respectively. Each
value in the reporter assay was presented as the fold increase in
Firefly luciferase activity units or b-galactosidase activity units per
Renilla luciferase activity units from three independent experi-
ments, each performed in triplicate.
Supporting Information
Table S1 List of Primers for EMSA
Found at: doi:10.1371/journal.pone.0010113.s001 (0.05 MB
DOC)
Table S2 List of Primers for qPCR
Found at: doi:10.1371/journal.pone.0010113.s002 (0.08 MB
DOC)
Table S3 List of Primers for Figure S1
Found at: doi:10.1371/journal.pone.0010113.s003 (0.05 MB
DOC)
Figure S1 mRNA expression levels in RCS cells compared to
Rat-2 fibroblast cells. Total RNA was extracted from logarithmi-
cally growing RCS cells or Rat-2 cells using Trizol reagent
(Invitrogen) according to the manufacturer’s protocol. cDNA was
prepared from the RNA using AMV reverse transcriptase followed
by qPCR with specific primer for each RNA (Table S3) using
SYBR Master Mix and ABI 7900 (Applied Biosystems). The
difference of Ct values (delta Ct) between the Ct value of each
sample and that of GAPDH was calculated. Then the delta Ct
value of each gene in RCS cells was compared to that value in
Rat-2 cells. The values on the Y axis show expression levels in
RCS cells compared to Rat-2 cells as log2y.
Found at: doi:10.1371/journal.pone.0010113.s004 (1.56 MB TIF)
Figure S2 Sequence conservation of peaks. By use of the
program, Multiz9way, obtained from UCSC genome browser, the
evolutionary conservation was measured in nine vertebrates
including rat, human, mouse, dog, cow, opossum, chicken, frog
and zebrafish. In order to calculate the conservation scores, 72
regions out of 76 peaks that contain the consensus inverted repeat,
WWCAAWG(N)nCWTTGWW (W is A or T, N is non-specified
base and n shows number of N.) with a space (n) of 3 to 6. These
regions also conserved a core inverted repeat sequence,
AANG(N)nCNTT, and had a maximum of 2 mismatches in each
half of the consensus repeat. 76 non-peak regions containing such
repeat were also chosen. Note that such sequences are frequently
found in both peak and non-peak regions of the genome. A two-
sample t-Test showed that p-value was 0.01864. Readers
interested in the detailed sequences that were used to compose
this figure should contact the corresponding author.
Found at: doi:10.1371/journal.pone.0010113.s005 (1.56 MB TIF)
Figure S3 Box plot showing AT content of peak and non-peak
regions. We compared AT or GC content in 610 bp sequences
centered on the hybridization peaks were compared to 610 bp
sequences surrounding random potential SOX9 binding sites
outside the peaks. The bold horizontal lines show the mean of the
data. Mean of AT content in peak regions was 46.7%, and mean
AT content in non-peak regions was 53.8%. By Student’s t-Test,
p-value was measured at 3.425610
29.
Found at: doi:10.1371/journal.pone.0010113.s006 (1.56 MB TIF)
Figure S4 Validation of SOX9 binding sites in Col2a1 on ChIP-
on-chip microarray by ChIP-qPCR. The DNA obtained from
ChIP of sheared chromatin of RCS cells with SOX9 antibodies
was used as the template in real time qPCR to amplify a segment
of intron 6 of Col2a1. A segment of intron 1 of Col2a1 previously
identified as containing a functional SOX9 binding sites and
another segment located 39 to the Col2a1 gene served as positive
and negative controls, respectively. Error bars represent standard
deviations. The sequence of each probe is shown in Table S2.
Found at: doi:10.1371/journal.pone.0010113.s007 (1.56 MB TIF)
Figure S5 Functional analysis of the SOX9 binding site in intron
6. Five tandem repeats of the 48bp in intron1, the 48bp in intron6
or the segment conjugated each other were inserted in 59 to the
Col2a1 minimal promoter (89bp) followed by the firefly luciferase
gene (Luc4) [67]. The activity of each construct was tested by
measuring the activity of each reporter in 293T (A) and RCS cells
(B). 293T cells were transiently transfected with the reporter
plasmids in the presence or absence of 0.5 mg of SOX9 expression
plasmid, whereas RCS cells were transfected only with the
reporter. Five tandem repeats of a 48 bp sequence in intron 1
(5xIn1) showed strong enhancer activity, but five tandem repeats
of an equivalent 48 bp in intron 6 (5xIn6) showed no
transcriptional activation. The duplication of this construct
(5xIn6, 5xIn6) did not show activity in either cell. However, the
combination of the intron 1 and intron 6 sequence (5xIn6, 5xIn1)
did not repress intron 1 enhancer activity in both cells and rather
increased slightly the activity in 293T cells (A). Each experiment
included 0.5 mg of the reporter plasmid and 0.01 mg of an internal
control plasmid, TK-Renilla luciferase construct, to normalize for
transfection efficiency.
Found at: doi:10.1371/journal.pone.0010113.s008 (1.56 MB TIF)
Figure S6 Conservation of the SOX9 binding site in intron 6
among different species. The sequences of Sox9 binding sites in
intron 6 of Col2a1 gene of three different species are aligned. The
inverted repeat of the rat SOX9 binding site is underlined. The
bases in red are the bases that are not identical to the
corresponding human sequence. The sequence of the binding
sites between rat and mouse are completely conserved. The
sequence of the binding site of the human is not identical to the rat
sequence. B. An EMSA assay was performed to test whether
SOX9 was binding to the human intron 6 sequence. The sequence
of each probe is shown in Table S3. The human putative SOX9
binding site binds SOX9 efficiently.
Found at: doi:10.1371/journal.pone.0010113.s009 (1.56 MB TIF)
Figure S7 Effect of mutation on the enhancer activity of Chimera
B shown in figure 3. The seven bases of 39 region of the 48bp of
intron 6 were mutated as follows. The bases mutated are shown by
italics. Wild: CTGGGTTTCTGTAAAGAAGGCCTTCAGC-
TATCTGA Mutant; CTGGGTTTCTGTCGAAAAGGAAAACA-
GCTATCTGA The ability of this mutated fragment to bind Sox9
was demonstrated as shown in Figure 2. Lane 1; Control probe
(SOX9 binding site of Col2a1intron 1),lane 2; SOX9 binding site of
Col2a1 intron 6, lane 3; mutant SOX9 binding site of Col2a1 intron
6.B.Luciferasereporterassayof ChimeraB andmutantChimera B
constructs. By use of this mutant fragment, the mutant Chimera B
(Figure 3) construct was prepared and its enhancer activity was
compared with wild ChimeraB constructusing RCScells. Reporter
assay was done as shown Figure 3. The mutant Chimera B did not
show the enhancer activity.
SOX9 Interaction Sites
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Figure S8 Depletion of histone H3 in 2
nd peak of Col2a1 gene in
primary chondrocyte. Binding of H3 and Sox9 in Col2a1 gene of
mouse rib chondrocyte primary culture and human lymphoblast,
Reh cells, was demonstrated by ChIP-qPCR The mouse
chondrocytes were cultured as shown previously [68]. The
ChIP-qPCR was performed as shown in Figure 4. The primers
used in this figure are shown in Table S2. 1
st peak and 2
nd peak
correspond to the peaks in intron 1 and intron 6 of rat Col2a1
gene, respectively. Expression of Col2a1 and Sox9 was detected in
primary chondrocyte cells but not in Reh cells by RT-qPCR
method shown in Figure S1. The sequence including SOX9
binding site corresponding to intron 6 of the mouse and rat Col2a1
gene is highly conserved in the human Col2a1 gene.
Found at: doi:10.1371/journal.pone.0010113.s011 (1.56 MB TIF)
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